北米の移植診断市場、製品タイプ別（移植診断機器、移植診断ソフトウェア、移植診断試薬）、技術別（PCR ベースの分子アッセイ、シーケンシング ベースの分子アッセイ）、移植タイプ別（固形臓器移植、幹細胞移植、軟部組織移植、骨髄移植、その他の移植）、アプリケーション別（診断アプリケーション、研究アプリケーション）、エンド ユーザー別（研究室および学術機関、病院および移植センター、商業サービス プロバイダー、その他）、流通チャネル別（直接入札、小売販売、その他）業界動向および 2029 年までの予測。
北米の移植診断市場の分析と洞察
移植診断は、通常、移植前と移植後の手順に分けられる診断手順です。患者の健康状態を分析するのに役立ちます。これを避けると、免疫不全の人は HAI またはそれ以上の病気を発症するリスクがあり、死に至る可能性があります。この手順は、医療専門家と検査室の専門家との調和のとれたコラボレーションであり、患者の転帰を改善します。さらに、ドナーとレシピエントの HLA マーカーの厳密な一致が重要です。これにより、移植片の生存の可能性が高まり、免疫学的移植の深刻な合併症が最小限に抑えられます。世界中の人口における慢性疾患の有病率の増加は、予測期間を通じて市場拡大を促進する可能性があります。さらに、幹細胞療法と個別化医薬品の使用の増加が人気を集めています。新しい診断技術の使用により、臓器移植の医療結果が改善されています。移植前にドナーとレシピエントの適合性を一致させることで、臓器拒絶率を減らすことができます。
しかし、PCR および NGS 診断機器に関連する手順のコストの高さは、最も重大な問題の 1 つです。その結果、市場の成長は長期的には妨げられる可能性があります。医療機器のコストは、重要な移植診断機器ベンダーにとって課題となる可能性のある要素の 1 つです。
Data Bridge Market Research の分析によると、北米の移植診断市場は、予測期間中に 6.9% の CAGR で成長し、2029 年までに 41 億 9,468 万米ドルに達すると予想されています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019～2014 にカスタマイズ可能) |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
製品タイプ別（移植診断機器、移植診断ソフトウェア、移植診断試薬）、技術別（PCR ベースの分子アッセイ、シーケンシングベースの分子アッセイ）、移植タイプ別（固形臓器移植、幹細胞移植、軟部組織移植、骨髄移植、その他）、用途別（診断アプリケーション、研究アプリケーション）、エンドユーザー別（研究機関および学術機関、病院および移植センター、商業サービスプロバイダー、その他）、流通チャネル別（直接入札、小売販売、その他） |
|
対象国 |
米国、カナダ、メキシコ |
|
対象となる市場プレーヤー |
Hologic, Inc.、Biofortuna Limited、Takara Bio Inc.、Abbott、Diagnóstica Longwood SL、Adaptive Biotechnologies、NanoString、Arquer Diagnostics Ltd、altona Diagnostics GmbH、ELITechGroup、DiaSorin SpA、Horiba Ltd、EUROFINS VIRACOR、CareDx Inc.、Laboratory Corporation of America Holdings.、Randox Laboratories Ltd.、Thermo Fisher Scientific Inc.、Preservation Solutions, Inc.、TransMedics、Transonic、Stryker、Bio-Rad Laboratories, Inc.、Zimmer Biomet、QIAGEN、F. Hoffmann-La Roche Ltd、BIOMÉRIEUX、Illumina, Inc.、Luminex Corporation (DiaSorin Company の子会社)、IMMUCOR など |
市場の定義
移植診断は、臓器および造血幹細胞移植の免疫遺伝学および組織適合性に関するものです。これらの診断は、医療従事者が潜在的なレシピエントと臓器提供者との適合性を判断するのに役立ちます。これらは、免疫遺伝学、病理学、感染症など、さまざまな分野で使用されています。移植診断は、臓器の提供者とレシピエントが移植前または移植後に適合性があるかどうかを判断するために使用されます。移植診断の導入により、移植前および移植後のスクリーニングを含む臓器不全を引き起こす可能性のある疾患の蔓延が爆発的に増加すると予想されます。これらのテストには移植手順の適合性を検証するための多くの利点があるため、市場は医療従事者の関心を集めています。臓器移植は、持続透析を受けている多くの末期腎不全患者にとって最も人気のある治療オプションの 1 つです。
さらに、心臓、肝臓、骨髄が関与するケースでは、臓器移植を調査することも可能です。ただし、多くの場合、末期腎不全を含む腎不全と肝移植の間には強い関連性があります。分子診断における新しいトランスクリプトーム、プロテオーム、ゲノム指標は、移植治療のより適切な調整と拒絶反応の早期検出に役立ちます。また、市場プレーヤーによる戦略的取り組み、移植診断における技術的進歩、高度な無菌性の保証、医療インフラへの投資の増加により、移植診断の需要が高まっています。
北米の移植診断市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 移植手術件数の増加
過去10年間、重要臓器不全の発生率増加と移植後の転帰の改善により、臓器移植の需要は世界中で急増しました。腎臓、心臓、肝臓、肺の移植の需要は非常に高くなっています。アルコール摂取、運動不足、薬物乱用は臓器不全の主な原因です。生体ドナー移植の数はCOVID-19パンデミックの影響を受けていますが、生体ドナー移植は2020年に比べて14.2％増加しています。
- さらに、臓器移植は患者の生存率と生活の質を向上させ、公衆衛生と臓器不全の社会経済的負担に大きなプラスの影響を与えます。欧州連合 (EU) は、臓器移植に対する比較的統一された構造化されたアプローチ、よく発達した国家プログラム、臓器共有を促進する国際システム、明確に定義された交換ポリシーを備えており、ヨーロッパはこの分野のリーダーとなっています。
したがって、世界中で移植手術の件数が増加し、移植の成功例も増えることで、北米の移植診断市場が拡大すると予想されます。
- 移植分野における技術進歩の増加
新しい技術により、臓器移植に対する従来のアプローチは急速に変化しています。臓器移植における主な課題は、生涯にわたる免疫抑制の必要性をいかにして特定し、可能であればその必要性をなくすか、そして、人体移植に適したドナーのプールをいかに拡大するかです。研究者は、ドナーの臓器がまだ体内にあると思わせることで、輸送時間を延長できる高度なシステムを開発しました。このシステムにより、臓器に酸素を含んだ血液が流れ続け、組織の死を遅らせます。常温灌流装置は人体を模倣し、臓器への一定の血流を確保します。この装置は、移植前に肝臓を最適な状態に保つために、薬剤やその他の栄養素を送達することもできます。
In addition, bio-artificial organ production techniques are a range of enabling techniques that can be used to produce human organs based on bionic principles. Over the past ten years, significant progress has been made in developing various organ manufacturing technologies. The past decade has seen tremendous advances in new technologies such as single-cell RNA sequencing, Nano biotechnology and CRISPR-Cas9 gene editing. However, creative applications of such new and powerful technologies to improve clinical transplantation have only begun. With such tools, there are now good opportunities to make major breakthroughs in defining and providing optimized and individualized care for all organ transplants.
Restraint
- High cost of organ transplantation
Organ transplantation therapy employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing players. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Also, organ transplants are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation and expensive medications.
- In addition, desensitizing therapies have also been used to achieve transplantation from an incompatible donor. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.
Thus, the high cost of transplantation and treatment using advanced modalities and technology products will act as a major restraining factor for the growth of the North America transplant diagnostics market.
Opportunity
-
Strategic initiatives by market players
The rise in the North America transplant diagnostics market increases the need for strategic business ideas. It includes a partnership, business expansion and other development. The surge in demand for a donor organs is significantly increasing the demand for transplant diagnostic kits. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.
These strategic initiatives, such as product launches, agreements and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the North America transplant diagnostics market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may be expected to as an opportunity that helps them to drive the North America transplant diagnostics market.
Challenge
- Ethical challenges faced during organ transplantation
The surge in the incidence of failure of vital organs and inadequate supply of organs has created a wide gap between organ supply and organ demand. The issue has resulted in long approval times to receive an organ and a rise in deaths. The events, which occurred in the previous years and continue in the present, have raised many ethical, moral and societal issues regarding supply, the methods of organ allocation and the use of living donors as volunteers, including minors.
Lack of accuracy in reporting, the donated organs can't be supplied and procedures that neither relieve suffering nor prolong life are rapidly identified.
Issues such as lack of organ procurement, religious acceptance, brain death and misconceptions related to organ donation and transplantation are still present on many ethical personal and community levels, even within the medical community. The various aspects of ethical, cultural and religious nature should not be a barrier to the act of organ donation and transplantation all of these are issues to be solved. Therefore, ethical challenges faced during organ transplantation are expected to challenge market growth.
Post-COVID-19 Impact on North America Transplant Diagnostics Market
North America transplant diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics has greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the North America transplant diagnostics market.
Recent Developments
- In July 2022, Horiba Medical launched a brand new product in its Yumizen Hematology Category. The product has new and advanced characteristics to satisfy the needs of various clinical as well as laboratory requirements. This has helped the company to diversify its product offerings
- In January 2022, Hoffmann-La Roche Ltd introduced Cobas Infinity edge, a cloud-based point-of-care platform accessible. With its advanced technology, healthcare practitioners can handle patient data. This has helped the company to diversify their product line
North America Transplant Diagnostics Market Scope
North America transplant diagnostics market is segmented into product type, technology, transplant type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product Type
- Transplant Diagnostic Instrument
- Transplant Diagnostic Software
- Transplant Diagnostic Reagent
On the basis of product type, the North America transplant diagnostics market is segmented into transplant diagnostic instrument, transplant diagnostic software, transplant diagnostic reagent.
Technology
- PCR-Based Molecular Assays
- Sequencing-Based Molecular Assays
On the basis of technology, the North America transplant diagnostics market is segmented into PCR-based molecular assays, and sequencing-based molecular assays.
Transplant Type
- Solid Organ Transplantation
- Stem Cell Transplantation
- Soft Tissue Transplantation
- Bone Marrow Transplantation
- Other Transplants
On the basis of transplant type, the North America transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, bone marrow transplantation, and other transplants.
Application
- Diagnostic Applications
- Research Applications
On the basis of application, the North America transplant diagnostics market is segmented into diagnostic applications and research applications.
End User
- Research Laboratories and Academic Institutes
- Hospitals and Transplant Centers
- Commercial Service Providers
- Others
On the basis of end user, the North America transplant diagnostics market is segmented into research laboratories and academic institutes, hospitals and transplant centers, commercial service providers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the North America transplant diagnostics market is segmented into direct tender, retail sales, and others.
North America Transplant Diagnostics Market Regional Analysis/Insights
North America transplant diagnostics market is analyzed, and market size information is provided by country, product type, technology, transplant type, application, end user, and distribution channel.
Some countries covered in the North America transplant diagnostics market are the U.S., Canada, and Mexico.
The U.S. is expected to dominate the North America transplant diagnostics market due to the presence of key market players in the largest consumer market with high GDP.
The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the market's current and future trends. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Transplant Diagnostics Market Share Analysis
北米移植診断市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、北米移植診断市場への会社の重点にのみ関連しています。
北米の移植診断市場で活動している主要企業としては、Hologic, Inc.、Biofortuna Limited、Takara Bio Inc.、Abbott、Diagnóstica Longwood SL、Adaptive Biotechnologies、NanoString、Arquer Diagnostics Ltd、altona Diagnostics GmbH、ELITechGroup、DiaSorin SpA、Horiba Ltd、EUROFINS VIRACOR、CareDx Inc.、Laboratory Corporation of America Holdings.、Randox Laboratories Ltd.、Thermo Fisher Scientific Inc.、Preservation Solutions, Inc.、TransMedics、Transonic、Stryker、Bio-Rad Laboratories, Inc.、Zimmer Biomet、QIAGEN、F. Hoffmann-La Roche Ltd、BIOMÉRIEUX、Illumina, Inc.、Luminex Corporation (DiaSorin Company の子会社)、IMMUCOR などがあります。
調査方法: 北米の移植診断市場
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、北米と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 EPIDEMOLOGY
3.2 PESTEL_ANALYSIS
3.3 PORTER'S FIVE FORCE
3.4 TECHNOLOGICAL INNOVATIONS
4 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS
5 KEY STRATEGIC INITIATIVES
6 INDUSTRIAL INSIGHTS:
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES
7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS
7.1.3 RISING HEALTHCARE SPENDING
7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF ORGAN TRANSPLANTATION
7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION
7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION
7.4 CHALLENGES
7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION
7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY
8 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS
8.2.1 AUTOMATED PIPETTORS & DISPENSERS
8.2.2 AUTOMATED SYSTEMS
8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM
8.2.2.2 PCR SETUP
8.2.2.3 OTHERS
8.2.3 NGS INSTRUMENTS
8.2.4 READERS & ANALYZERS
8.2.5 TRANSPLANT DIAGNOSTIC KITS
8.2.5.1 ASPERGILLUS SPP KITS
8.2.5.2 P. JIROVECII KITS
8.2.5.3 CMV KITS
8.2.5.4 EBV KITS
8.2.5.5 BKV KITS
8.2.5.6 VZV KITS
8.2.5.7 HSV1 KITS
8.2.5.8 HSV2 KITS
8.2.5.9 PARVOVIRUS B19 KITS
8.2.5.10 ADENOVIRUS KITS
8.2.5.11 ENTEROVIRUS KITS
8.2.5.12 JCV KITS
8.2.5.13 HHV6 KITS
8.2.5.14 HHV7 KITS
8.2.5.15 HHV8 KITS
8.2.5.16 TOXOPLASMA GONDII KITS
8.2.5.17 HEPATITIS E KITS
8.2.5.18 OTHER KITS
8.2.6 OTHER KITS
8.3 TRANSPLANT DIAGNOSTIC SOFTWARE’S
8.3.1 DNA SOFTWARE
8.3.2 NGS SOFTWARE
8.3.3 DATA MANAGEMENT SOFTWARE
8.3.4 OTHER SOFTWARE’S
8.4 TRANSPLANT DIAGNOSTIC REAGENTS
8.4.1 MONOCLONAL ANTIBODIES
8.4.2 CYTOTOXIC CONTROLS
8.4.3 HUMAN SERUM
8.4.4 OTHER REAGENTS
9 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 PCR-BASED MOLECULAR ASSAYS
9.2.1 REAL TIME PCR
9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR
9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR
9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP)
9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS
9.3 SEQUENCING-BASED MOLECULAR ASSAYS
9.3.1 SANGER SEQUENCING
9.3.2 NEXT GENERATION SEQUENCING
9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS.
10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE
10.1 OVERVIEW
10.2 SOLID ORGAN TRANSPLANTATION
10.2.1 KIDNEY TRANSPLANTATION
10.2.2 LIVER TRANSPLANTATION
10.2.3 HEART TRANSPLANTATION
10.2.4 LUNG TRANSPLANTATION
10.2.5 PANCREAS TRANSPLANTATION
10.2.6 OTHER ORGAN TRANSPLANTATIONS
10.3 STEM CELL TRANSPLANTATION
10.3.1 BONE MARROW TRANSPLANT (BMT)
10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT
10.3.3 CORD BLOOD TRANSPLANT
10.3.4 OTHER STEM CELL TRANSPLANTS
10.4 SOFT TISSUE TRANSPLANTATION
10.4.1 SKIN GRAFT
10.4.2 CARTILAGE TRANSPLANTATION
10.4.3 ADRENAL AUTOGRAFTING
10.4.4 OTHER SOFT TISSUE TRANSPLANTATION.
10.5 BONE MARROW TRANSPLANTATION
10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT
10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT
10.5.3 UMBILICAL CORD BLOOD TRANSPLANT.
10.6 OTHERS
11 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DIAGNOSTIC APPLICATIONS
11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT
11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS
11.2.1.2 AUTOMATED SYSTEMS
11.2.1.3 NGS INSTRUMENTS
11.2.1.4 READERS & ANALYZERS
11.2.1.5 TRANSPLANT DIAGNOSTIC KITS
11.2.1.6 OTHERS
11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE
11.2.2.1 DNA SOFTWARE
11.2.2.2 NGS SOFTWARE
11.2.2.3 DATA MANAGEMENT SOFTWARE
11.2.2.4 OTHER SOFTWARES
11.2.3 TRANSPLANT DIAGNOSTIC REAGENT
11.2.3.1 MONOCLONAL ANTIBODIES
11.2.3.2 CYTOTOXIC CONTROLS
11.2.3.3 HUMAN SERUM
11.2.3.4 OTHER REAGENTS
11.3 RESEARCH APPLICATIONS
11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT
11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS
11.3.1.2 AUTOMATED SYSTEMS
11.3.1.3 NGS INSTRUMENTS
11.3.1.4 READERS & ANALYZERS
11.3.1.5 TRANSPLANT DIAGNOSTIC KITS
11.3.1.6 OTHERS
11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE
11.3.2.1 DNA SOFTWARE
11.3.2.2 NGS SOFTWARE
11.3.2.3 DATA MANAGEMENT SOFTWARE
11.3.2.4 OTHER SOFTWARES
11.3.3 TRANSPLANT DIAGNOSTIC REAGENT
11.3.3.1 MONOCLONAL ANTIBODIES
11.3.3.2 CYTOTOXIC CONTROLS
11.3.3.3 HUMAN SERUM
11.3.3.4 OTHER REAGENTS
12 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS AND TRANSPLANT CENTERS
12.3 COMMERCIAL SERVICE PROVIDERS
12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
12.5 OTHERS
13 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.4 OTHERS
14 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 F. HOFFMANN LA ROCHE LTD
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 TAKARA BIO INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 HOLOGIC, INC
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ADAPTIVE BIOTECHNOLOGIES
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ALTONA DIAGNOSTICS
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ARQUER DIAGNOSTICS LTD
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 BAG DIAGNOSTICS GMBH
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BIOFORTUNA LIMITED
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BIOMÉRIEUX
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BIO-RAD LABORATORIES, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOTYPE GMBH
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 CAREDX INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 CLONIT SRL
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 DIAGNOSTICA LONGWOOD SL
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 DIASORIN S.P.A.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 ELITECHGROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 EUROFINS VIRACOR
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 HORIBA LTD
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 ILLUMINA, INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 IMMUCOR
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENTS
17.23 LABORATORY CORPORATION OF AMERICA HOLDINGS.
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 LUMINEX CORPORATION. (A SUBSIDIARY OF DIASORIN)
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 NANOSTRING
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 PATHONOSTICS
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENTS
17.27 PRESERVATION SOLUTIONS, INC.
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 QIAGEN
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 RANDOX LABORATORIES LTD.
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
17.3 STRYKER
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENT
17.31 TRANSMEDICS
17.31.1 COMPANY SNAPSHOT
17.31.2 REVENUE ANALYSIS
17.31.3 PRODUCT PORTFOLIO
17.31.4 RECENT DEVELOPMENTS
17.32 TRANSONIC.
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENT
17.33 ZIMMER BIOMET
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE’S IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE’S IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA SEQUENCING-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA BONE MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA BONE MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA DIAGNOSTIC APPLICATIONS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH APPLICATIONS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA RESEARCH APPLICATIONS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA TRANSPLANT DIAGNOSTIC INSTRUMENTS IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS AND TRANSPLANT CENTERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA COMMERCIAL SERVICE PROVIDERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA RESEARCH LABORATORIES AND ACADEMIC INSTITUTES IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA DIRECT TENDER IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA RETAIL SALES IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN TRANSPLANT DIAGNOSTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 62 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 65 NORTH AMERICA RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 66 NORTH AMERICA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 68 NORTH AMERICA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 69 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 72 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.S. AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 74 U.S. AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 75 U.S. AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.S. TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 77 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 78 U.S. TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 79 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 80 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 82 U.S. TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 83 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 84 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 86 U.S. TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 87 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 U.S. PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 U.S. SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 90 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 91 U.S. SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.S. STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.S. SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 94 U.S. BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 95 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 U.S. DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.S. RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 101 U.S. TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.S. TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.S. TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 104 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 105 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 106 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 108 CANADA AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 109 CANADA AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 110 CANADA AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 CANADA TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 112 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 113 CANADA TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 114 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 115 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 116 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 117 CANADA TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 118 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 119 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 120 CANADA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 121 CANADA TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 122 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 123 CANADA PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 124 CANADA SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 125 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 126 CANADA SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 127 CANADA STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 128 CANADA SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 129 CANADA BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 130 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 CANADA DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 132 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 133 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 134 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 135 CANADA RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 136 CANADA TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 137 CANADA TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 138 CANADA TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 139 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 142 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 143 MEXICO AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 VOLUME (UNITS)
TABLE 144 MEXICO AUTOMATED PIPETTORS & DISPENSERS, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 145 MEXICO AUTOMATED SYSTEMS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 146 MEXICO TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 147 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 148 MEXICO TRANSPLANT DIAGNOSTIC INSTUMENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 149 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 150 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 151 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 152 MEXICO TRANSPLANT DIAGNOSTIC KITS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 153 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 154 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 155 MEXICO TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 VOLUMES (UNITS)
TABLE 156 MEXICO TRANSPLANT DIAGNOSTIC REAGENTS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 ASP (USD)
TABLE 157 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 158 MEXICO PCR-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 159 MEXICO SEQUENCE-BASED MOLECULAR ASSAYS IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 160 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 161 MEXICO SOLID ORGAN TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 162 MEXICO STEM CELL TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 163 MEXICO SOFT TISSUE TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 164 MEXICO BONE-MARROW TRANSPLANTATION IN TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE, 2020-2029 (USD MILLION)
TABLE 165 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 166 MEXICO DIAGNOSTICS APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 167 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 168 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 169 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 170 MEXICO RESEARCH APPLICATIONS TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 171 MEXICO TRANSPLANT DIAGNOSTICS INSTRUMENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 172 MEXICO TRANSPLANT DIAGNOSTIC SOFTWARE IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 173 MEXICO TRANSPLANT DIAGNOSTIC REAGENT IN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 175 MEXICO TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 INCREASING USE OF TRANSPLANT DIAGNOSTICS IS EXPECTED TO DRIVE THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 TRANSPLANT DIAGNOSTIC INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2021
FIGURE 15 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2021
FIGURE 19 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 22 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2021
FIGURE 23 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2021
FIGURE 27 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2021
FIGURE 31 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 43 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
